These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 19628430)
41. [Angiogenesis and anti-angiogenic strategies for glioblastoma]. de Boüard S; Guillamo JS Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393 [TBL] [Abstract][Full Text] [Related]
42. Bevacizumab on the PBS. Kingston D Aust Fam Physician; 2007 Sep; 36(9):680. PubMed ID: 17915374 [No Abstract] [Full Text] [Related]
43. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth. Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139 [TBL] [Abstract][Full Text] [Related]
45. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Simpson L; Galanis E Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364 [TBL] [Abstract][Full Text] [Related]
46. First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment? Marosi C CNS Oncol; 2013 Nov; 2(6):473-4. PubMed ID: 25054815 [No Abstract] [Full Text] [Related]
47. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme. Spasic M; Chow F; Tu C; Nagasawa DT; Yang I Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654 [TBL] [Abstract][Full Text] [Related]
48. Update on the therapeutic approaches to brain tumors. Lallana EC; Abrey LE Expert Rev Anticancer Ther; 2003 Oct; 3(5):655-70. PubMed ID: 14599089 [TBL] [Abstract][Full Text] [Related]
49. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Johnson DR; Leeper HE; Uhm JH Cancer; 2013 Oct; 119(19):3489-95. PubMed ID: 23868553 [TBL] [Abstract][Full Text] [Related]
50. Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Verhoeff JJ; Stalpers LJ; Van Noorden CJ; Troost D; Ramkema MD; van Bree C; Song JY; Donker M; Chekenya M; Vandertop WP; Richel DJ; van Furth WR Cancer Lett; 2009 Nov; 285(1):39-45. PubMed ID: 19473756 [TBL] [Abstract][Full Text] [Related]
51. Bevacizumab for the treatment of glioblastoma. Chowdhary S; Chamberlain M Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194 [TBL] [Abstract][Full Text] [Related]
54. Plants versus tumors: the search for new targets in neuro-oncology. Welling LC; Figueiredo EG; Teixeira MJ World Neurosurg; 2012 Jul; 78(1-2):7-8. PubMed ID: 22634151 [No Abstract] [Full Text] [Related]
55. Susceptibility-weighted imaging at ultra-high field (7 T) in the evaluation of brain tumors. Zee CS; Yan C World Neurosurg; 2012; 77(5-6):654-6. PubMed ID: 22381318 [No Abstract] [Full Text] [Related]
57. Fearful of Avastin's fate, Genentech asks for unusual hearing. Ratner M Nat Med; 2011 Mar; 17(3):233. PubMed ID: 21383702 [No Abstract] [Full Text] [Related]
58. The avastin story. Sekeres MA N Engl J Med; 2011 Oct; 365(15):1454-5. PubMed ID: 21995408 [No Abstract] [Full Text] [Related]
59. Bringing the endovascular neurosurgeon into the neuro-oncology treatment team. Peruzzi P; Chiocca EA World Neurosurg; 2012 Jan; 77(1):59-61. PubMed ID: 22405385 [No Abstract] [Full Text] [Related]